Wells Fargo’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $94 | Hold |
13
| – | – | ﹤0.01% | 6647 |
|
|
2026
Q1 | $142 | Sell |
13
-24
| -65% | -$328 | ﹤0.01% | 6476 |
|
|
2025
Q4 | $467 | Hold |
37
| – | – | ﹤0.01% | 6340 |
|
|
2025
Q3 | $682 | Hold |
37
| – | – | ﹤0.01% | 6281 |
|
|
2025
Q2 | $934 | Buy |
37
+24
| +185% | +$482 | ﹤0.01% | 6313 |
|
|
2025
Q1 | $250 | Hold |
13
| – | – | ﹤0.01% | 6315 |
|
|
2024
Q4 | $228 | Hold |
13
| – | – | ﹤0.01% | 6351 |
|
|
2024
Q3 | $375 | Sell |
13
-10
| -43% | -$219 | ﹤0.01% | 6186 |
|
|
2024
Q2 | $319 | Sell |
23
-17
| -43% | -$295 | ﹤0.01% | 6177 |
|
|
2024
Q1 | $757 | Buy |
40
+13
| +48% | +$253 | ﹤0.01% | 6214 |
|
|
2023
Q4 | $601 | Buy |
27
+1
| +4% | +$30 | ﹤0.01% | 6341 |
|
|
2023
Q3 | $987 | Sell |
26
-1
| -4% | -$57 | ﹤0.01% | 6206 |
|
|
2023
Q2 | $1.93K | Buy |
27
+1
| +4% | +$63 | ﹤0.01% | 6210 |
|
|
2023
Q1 | $1.77K | Hold |
26
| – | – | ﹤0.01% | 6250 |
|
|
2022
Q4 | $807 | Sell |
26
-200
| -88% | -$5.94K | ﹤0.01% | 6254 |
|
|
2022
Q3 | $6K | Sell |
226
-2
| -0.9% | -$78 | ﹤0.01% | 5846 |
|
|
2022
Q2 | $10K | Sell |
228
-684
| -75% | -$31.4K | ﹤0.01% | 5743 |
|
|
2022
Q1 | $59K | Sell |
912
-739
| -45% | -$52.9K | ﹤0.01% | 5570 |
|
|
2021
Q4 | $139K | Buy |
1,651
+1,183
| +253% | +$133K | ﹤0.01% | 5468 |
|
|
2021
Q3 | $76K | Buy |
468
+3
| +0.6% | +$487 | ﹤0.01% | 5480 |
|
|
2021
Q2 | $71K | Sell |
465
-4,741
| -91% | -$799K | ﹤0.01% | 5425 |
|
|
2021
Q1 | $903K | Sell |
5,206
-32
| -0.6% | -$6.1K | ﹤0.01% | 4313 |
|
|
2020
Q4 | $835K | Buy |
5,238
+79
| +2% | +$13.2K | ﹤0.01% | 4165 |
|
|
2020
Q3 | $823K | Buy |
5,159
+478
| +10% | +$86.3K | ﹤0.01% | 4002 |
|
|
2020
Q2 | $926K | Buy |
4,681
+2,997
| +178% | +$550K | ﹤0.01% | 3869 |
|
|
2020
Q1 | $260K | Buy |
1,684
+508
| +43% | +$51.3K | ﹤0.01% | 4502 |
|
|
2019
Q4 | $91K | Sell |
1,176
-129
| -10% | -$11.3K | ﹤0.01% | 5339 |
|
|
2019
Q3 | $132K | Buy |
1,305
+44
| +3% | +$5.12K | ﹤0.01% | 5188 |
|
|
2019
Q2 | $167K | Sell |
1,261
-1,744
| -58% | -$240K | ﹤0.01% | 5072 |
|
|
2019
Q1 | $455K | Buy |
3,005
+208
| +7% | +$32.4K | ﹤0.01% | 4395 |
|
|
2018
Q4 | $452K | Buy |
2,797
+770
| +38% | +$153K | ﹤0.01% | 4395 |
|
|
2018
Q3 | $522K | Sell |
2,027
-868
| -30% | -$218K | ﹤0.01% | 4403 |
|
|
2018
Q2 | $660K | Buy |
2,895
+1,853
| +178% | +$351K | ﹤0.01% | 4261 |
|
|
2018
Q1 | $147K | Sell |
1,042
-4
| -0.4% | -$605 | ﹤0.01% | 5137 |
|
|
2017
Q4 | $136K | Buy |
1,046
+675
| +182% | +$85.9K | ﹤0.01% | 5169 |
|
|
2017
Q3 | $46K | Buy |
+371
| New | +$37.8K | ﹤0.01% | 5495 |
|
|
2017
Q1 | – | Sell |
-75
| Closed | -$8K | – | 6323 |
|
|
2016
Q4 | $8K | Buy |
+75
| New | +$8.21K | ﹤0.01% | 5855 |
|
|
2016
Q2 | – | Sell |
-63
| Closed | -$5K | – | 6122 |
|
|
2016
Q1 | $5K | Sell |
63
-453
| -88% | -$39.3K | ﹤0.01% | 5859 |
|
|
2015
Q4 | $57K | Buy |
+516
| New | +$70.3K | ﹤0.01% | 5232 |
|
|
2015
Q3 | – | Sell |
-6
| Closed | -$1K | – | 6229 |
|
|
2015
Q2 | $1K | Sell |
6
-17
| -74% | -$2.31K | ﹤0.01% | 6223 |
|
|
2015
Q1 | $6K | Buy |
+23
| New | +$4.73K | ﹤0.01% | 5772 |
|
Other funds holding CTSO
CM
Wells Fargo's CTSO Position: Q2 2026 in Review
Wells Fargo held its Cytosorbents Corp (CTSO) position steady in Q2 2026 at 13 shares worth $94. The position accounts for ﹤0.01% of the portfolio, ranked #6647.
Wells Fargo first reported a position in CTSO in Q1 2015 and has held it in 41 quarters since. The position peaked at $926K in Q2 2020. 47 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.
- Wells Fargo held 13 shares of Cytosorbents Corp worth $94 as of Q2 2026.
- Wells Fargo left its Cytosorbents Corp share count unchanged in Q2 2026.
- Cytosorbents Corp made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6647 holding.
- Wells Fargo first reported a position in Cytosorbents Corp in Q1 2015 and has held it in 41 quarters since.
- Wells Fargo's Cytosorbents Corp position peaked at $926K in Q2 2020.
- 47 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.